FDA Device Intelligence
HomeEdwards Lifesciences LLC › EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE (THV)

EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE (THV)

Edwards Lifesciences LLC · Model 9300TFX · UDI-DI 00690103192087

NPTNPV
0
510(k) clearances
79,061
Adverse events (8,008 deaths)
33
Recalls
25
Facilities

Description

EDWARDS SAPIEN XT TRANSCATHETER HEART VALVE (26MM)

Recalls

DateFirmReason
2024-10-17Abbott MedicalA manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term dura
2024-10-17Abbott MedicalA manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term dura
2024-10-17Abbott MedicalA manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term dura
2024-10-17Abbott MedicalA manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term dura
2024-10-17Abbott MedicalA manufacturing error resulting in acceptance of valves with a leaflet deflection value that was outside of established specifications. This could potentially affect long-term dura
2021-06-11Medtronic Heart Valves DivisionDue to reports of actuator separation for various delivery catheter systems. Affected products were manufactured before July 11, 2020.
2021-06-11Medtronic Heart Valves DivisionDue to reports of actuator separation for various delivery catheter systems. Affected products were manufactured before July 11, 2020.
2021-06-11Medtronic Heart Valves DivisionDue to reports of actuator separation for various delivery catheter systems. Affected products were manufactured before July 11, 2020.
2020-11-17Boston Scientific CorporationFailure to execute the visual inspection correctly prior to locking the valve during the deployment process can lead to the inability to release the delivery system.
2020-11-17Boston Scientific CorporationFailure to execute the visual inspection correctly prior to locking the valve during the deployment process can lead to the inability to release the delivery system.

Query this across every FDA database — by API.

Linked GUDID · 510(k)/PMA · MAUDE · recalls · establishments. Free tier, no card required.

Get your free API keyRead the docs
Data compiled from public U.S. FDA sources (GUDID, 510(k)/PMA, MAUDE, recalls, establishment registration). Adverse-event reports are unverified and do not establish causation. Informational only — not medical, clinical, or regulatory advice.